Investigating RNA modifications in aggressive prostate cancer treatment
Targeting m6A RNA epigenetics in treatment-emergent neuroendocrine prostate cancer
This study is looking at how certain changes in RNA might affect the way treatment-resistant neuroendocrine prostate cancer develops, with the hope of finding new ways to help patients fight this tough form of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11076752 on NIH RePORTER |
What this research studies
This research focuses on understanding how specific RNA modifications, particularly N6-methyladenosine (m6A), influence the progression of treatment-emergent neuroendocrine prostate cancer (t-NEPC). By analyzing various molecular profiles and using both laboratory and animal models, the study aims to identify new therapeutic targets that could help combat this aggressive form of prostate cancer. The goal is to uncover the mechanisms behind the cancer's resistance to standard treatments, which could lead to more effective therapies for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with treatment-emergent neuroendocrine prostate cancer or those experiencing resistance to androgen receptor-targeted therapies.
Not a fit: Patients with early-stage prostate cancer or those whose cancer is still responsive to standard androgen receptor therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with advanced prostate cancer that no longer responds to current therapies.
How similar studies have performed: Other research has shown promising results in targeting RNA modifications in various cancers, suggesting that this approach may also be effective in prostate cancer.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Song, Min Sup — University of Tx Md Anderson Can Ctr
- Study coordinator: Song, Min Sup
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.